SOD2 and neurodegenerative disease: On the other hand, post-mortem neuropathological studies have reported an enhanced SOD2 immunoreactivity in astrocytes in several neurodegenerative diseases such as ALS [104, 105] and FTLD-tau and TDP-43 [106], suggesting the existence of a mismatch either between mRNA and protein levels or between human disease and mouse models.